Last Updated : May 20, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name Sort ascending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Omnitrope | Somatropin (rDNA origin) | Growth hormone deficiency in children and adults | N/A | Complete | ||
Genotropin | Somatropin | Growth hormone deficiency, adult | List with criteria/condition | Complete | ||
Genotropin | Somatropin | Growth hormone deficiency, children | List with criteria/condition | Complete | ||
Genotropin | Somatropin | Turner Syndrome | List with criteria/condition | Complete | ||
Ngenla | somatrogon | Growth hormone deficiency | Reimburse with clinical criteria and/or conditions | Complete | ||
Sogroya | somapacitan | Growth Hormone Deficiency (GHD) | Reimburse with clinical criteria and/or conditions | Complete | ||
VesiFlow | Solifenacin succinate / tamsulosin hydrochloride | Benign prostatic hyperplasia | Withdrawn | |||
Vesicare | Solifenacin succinate | Bladder, overactive | List with clinical criteria and/or conditions | Complete | ||
Vesicare | Solifenacin succinate | Bladder, overactive | Do not list | Complete | ||
Epclusa | Sofosbuvir/ velpatasvir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete |